Rydapt Archives -

Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

https://pharmaphorum.com/news/eha-survival-data-sets-daiichi-sankyos-quizartinib-back-on-track/

Novartis’ Rydapt has become the first and only licensed treatment for rare and life-threatening blood disorder systemic mastocytosis

NICE says yes to Novartis’ Rydapt for rare blood disorder

https://pharmaphorum.com/news/nice-says-yes-to-novartis-rydapt-for-rare-blood-disorder/

Blueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM),

Blueprint’s latest approval for Ayvakit sets up clash with Novartis

https://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/

Rydapt